WARD Glucose Pilot

WARD Glucose Pilot

Principal Investigator

Eske Kvanner Aasvang

Christian S. Meyhoff,

Helge Dissing Sørensen

Study design
Prospective study/cohort
Sample size
70 participants
Study sites

Rigshospitalet and Bispebjerg Hospital

Inclusion criteria
  • Adult patients (≥18 years) admitted to Rigshospitalet or Bispebjerg Hospital for major abdominal surgery (e.g. colonic resections, gastrectomy, hepatic resection etc.) or major orthopedic surgery (e.g. hip-fracture, hip and knee-arthroplasty) or major arterial vascular surgery (e.g. aortic aneurysm, iliac or femoral bypass etc.)
  • Estimated duration of surgery ≥1 hour and at least one expected overnight stay postoperatively

AND

● Type 1 diabetes (Clinically defined: insulin initiated at diabetes onset and treatment with multiple doses of insulin or continuous subcutaneous insulin infusion) (n=20)

OR

● Type 2 diabetes treated with insulin (Clinically defined: treatment with diet or oral antidiabetic drugs for at least 6 months before insulin was started) (n =20)

OR

● Type 2 diabetes treated with oral antihyperglycemic drugs and/or GLP-1 analogs (n=20)

OR

● No diabetes mellitus (excluded by an admission HbA1c <48 mmol/mol) (n=20)

Study procedures

A Dexcom G6 sensor measured glucose during surgery and for up to ten days afterwards. Patients and staff could not see the sensor readings and followed usual diabetes care. Researchers also recorded vital signs and 30-day complications.

Outcome

Low glucose episodes lasting at least 15 minutes occurred in 43% of the 70 patients and in 70% of those with type 1 diabetes. Both low and high glucose occurred despite usual perioperative diabetes care.

Trial registration
NCT04473001

–  Read more